Key Events This Week
May 11: New 52-week high at Rs.2,550 and all-time high near Rs.2,548
May 12: Sharp correction of 6.34% amid broader market sell-off
May 14: Modest recovery with 1.32% gain supported by technical strength
May 15: Week closes at Rs.2,366.45, down 0.36% for the week but outperforming Sensex
May 11: Stock Hits New 52-Week and All-Time Highs Amid Strong Financials
Fredun Pharmaceuticals Ltd surged impressively on 11 May 2026, reaching a new 52-week high of Rs.2,550 and an all-time intraday peak of Rs.2,547.95. The stock closed near this peak at Rs.2,530.00, registering a day gain of 6.15% (Rs.145.95), significantly outperforming the Sensex which declined 1.40% that day. This rally was supported by the company’s robust financial performance, including a 56.70% year-over-year increase in quarterly net sales to Rs.160.93 crores and a near doubling of operating profit by 99.09% to Rs.26.34 crores in the December 2025 quarter.
Technical indicators were strongly bullish, with the stock trading above all key moving averages and exhibiting positive momentum across MACD, Bollinger Bands, and Dow Theory signals. Promoter confidence was also evident, with a 1.11% increase in stake to 44.17%, reinforcing market optimism. The stock’s one-year return of 265.24% dwarfed the Sensex’s 4.36% decline, highlighting its exceptional outperformance within the pharmaceuticals sector.
Only 1% make it here. This Large Cap from the Gems, Jewellery And Watches sector passed our rigorous filters with flying colors. Be among the first few to spot this gem!
- - Highest rated stock selection
- - Multi-parameter screening cleared
- - Large Cap quality pick
May 12: Sharp Correction Amid Broader Market Weakness
The following day, Fredun Pharmaceuticals faced a significant pullback, closing at Rs.2,361.00, down 6.34% (Rs.159.90). This decline coincided with a steep Sensex drop of 2.19%, reflecting broader market volatility and profit-taking after the prior day’s sharp gains. Despite the correction, the stock’s volume remained elevated at 10,807 shares, indicating continued investor interest. The decline brought the stock closer to its 20-day moving average support, which technical analysts often watch for potential stabilisation.
May 13-14: Stabilisation and Modest Recovery
On 13 May, the stock price stabilised, closing marginally lower by 0.07% at Rs.2,359.40, while the Sensex rebounded slightly by 0.32%. The following day, 14 May, saw a modest recovery with a 1.32% gain to Rs.2,390.55, supported by a 1.01% rise in the Sensex. These sessions reflected a consolidation phase after the volatility earlier in the week, with the stock maintaining levels above Rs.2,350 and technical indicators continuing to signal underlying strength.
Want to dive deeper on Fredun Pharmaceuticals Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
May 15: Week Closes Slightly Lower but Outperforms Sensex
Fredun Pharmaceuticals ended the week on 15 May at Rs.2,366.45, down 1.01% on the day and 0.36% for the week. This modest decline contrasted with the Sensex’s 0.36% drop on the day and a 2.63% fall over the week, indicating relative outperformance by the stock. Trading volume remained steady at 9,221 shares. The stock’s ability to hold above Rs.2,360 despite broader market weakness reflects underlying investor confidence and the strength of its fundamentals.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-05-11 | Rs.2,520.90 | +6.15% | 35,679.54 | -1.40% |
| 2026-05-12 | Rs.2,361.00 | -6.34% | 34,899.09 | -2.19% |
| 2026-05-13 | Rs.2,359.40 | -0.07% | 35,010.26 | +0.32% |
| 2026-05-14 | Rs.2,390.55 | +1.32% | 35,364.44 | +1.01% |
| 2026-05-15 | Rs.2,366.45 | -1.01% | 35,236.50 | -0.36% |
Key Takeaways from the Week
Robust Financial Performance: The company’s strong quarterly results, including a 56.70% increase in net sales and a near doubling of operating profit, underpin the stock’s recent rally and technical strength.
Promoter Confidence: An increase in promoter stake to 44.17% signals management’s positive outlook and commitment to the company’s growth trajectory.
Technical Momentum: The stock’s trading above all major moving averages and bullish technical indicators suggest sustained upward momentum despite short-term volatility.
Market Volatility Impact: The sharp correction on 12 May reflects broader market weakness, yet Fredun Pharmaceuticals outperformed the Sensex over the week, highlighting relative resilience.
Valuation Considerations: While the stock trades at a premium with a price-to-earnings ratio of 40x and PEG of 0.71, its strong earnings growth and operational metrics provide justification for the valuation.
Conclusion
Fredun Pharmaceuticals Ltd’s week was marked by a significant milestone with new 52-week and all-time highs on 11 May, driven by strong financial results and positive technical signals. Despite a midweek correction amid broader market weakness, the stock demonstrated resilience by outperforming the Sensex over the week. The company’s consistent quarterly growth, rising promoter confidence, and robust operational metrics continue to support its market position. Investors should note the stock’s premium valuation alongside its strong earnings momentum as it navigates ongoing market volatility.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
